We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among patients with nonalcoholic steatohepatitis in the ...

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty ...

BOSTON--(BUSINESS WIRE)--Care Access—a global research site enabling clinical research participation for more people—is actively enrolling participants at its Pottsville, Pa., location to study the ...

The FINANCIAL — The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover ...

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no current cure, but a drug called resmetirom may offer a lifeline for millions of patients, promoting a better quality of life ...

When left uncontrolled, fatty liver disease can progress to severe conditions, including non-alcoholic steatohepatitis (NASH) ...

The FDA decision follows the Company’s Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021 The FDA’s dedicated Fast Track program is designed to ...

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (GALT) (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging ...

--Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis, today announced results from new analyses of the Phase 3 ...

The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...

Paris (Reuters) - French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for liver disease NASH by year-end as part of an accelerated approval ...